Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/65673
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Baune, B. | - |
dc.contributor.author | Hohoff, C. | - |
dc.contributor.author | Berger, K. | - |
dc.contributor.author | Neumann, A. | - |
dc.contributor.author | Mortensen, S. | - |
dc.contributor.author | Roehrs, T. | - |
dc.contributor.author | Deckert, J. | - |
dc.contributor.author | Arolt, V. | - |
dc.contributor.author | Domschke, K. | - |
dc.date.issued | 2008 | - |
dc.identifier.citation | Neuropsychopharmacology, 2008; 33(4):924-932 | - |
dc.identifier.issn | 0893-133X | - |
dc.identifier.issn | 1740-634X | - |
dc.identifier.uri | http://hdl.handle.net/2440/65673 | - |
dc.description.abstract | In several previous biochemical, pharmacological, and genetic studies, the catechol-O-methyltransferase (COMT) has been suggested to be involved in the pathogenesis as well as the pharmacological treatment of affective disorders. In the present study, 256 patients with major depression (DSM-IV) of Caucasian descent were genotyped for the functional COMT val158met polymorphism and characterized for clinical response to antidepressive pharmacological treatment as measured by intra-individual changes of Hamilton Depression (HAM-D-21) scores over 6 weeks. The COMT 158val/val genotype conferred a significant risk of worse response after 4–6 weeks of antidepressant treatment in patients with major depression (week 4: p=0.003; week 5: p<0.0001; week 6: p<0.0001) after Bonferroni correction for multiple comparisons. The present results strongly point toward a negative influence of the higher activity COMT 158val/val genotype on antidepressant treatment response during the first 6 weeks of pharmacological treatment in major depression, possibly conferred by consecutively decreased dopamine availability. This finding suggests a potentially beneficial effect of an antidepressive add-on therapy with substances increasing dopamine availability individually tailored according to COMT val158met genotype. | - |
dc.description.statementofresponsibility | Bernhard T Baune, Christa Hohoff, Klaus Berger, Anna Neumann, Sünke Mortensen, Tilmann Roehrs, Jürgen Deckert, Volker Arolt and Katharina Domschke | - |
dc.language.iso | en | - |
dc.publisher | Elsevier Science Inc | - |
dc.rights | © 2008 Nature Publishing Group. All rights reserved. | - |
dc.source.uri | http://dx.doi.org/10.1038/sj.npp.1301462 | - |
dc.subject | major depression | - |
dc.subject | catechol-O-methyltransferase | - |
dc.subject | COMT val158met | - |
dc.subject | polymorphism | - |
dc.subject | antidepressants | - |
dc.subject | treatment response | - |
dc.title | Association of the COMT val158met Variant with Antidepressant Treatment Response in Major Depression | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.1038/sj.npp.1301462 | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | Baune, B. [0000-0001-6548-426X] | - |
Appears in Collections: | Aurora harvest Psychiatry publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.